Towards a More Efficient Breast Cancer Therapy Using Active Human Cell Membrane-Coated Metal–Organic Frameworks
Metadata
Show full item recordAuthor
Graván, Pablo; Rojas Macías, Sara; Picchi, Darina Francesca; Galisteo González, Francisco; Horcajada, Patricia; Marchal Corrales, Juan AntonioEditorial
MDPI
Materia
Metal–organic frameworks Coating Human cell membrane
Date
2024-04-30Referencia bibliográfica
Graván, P.; Rojas, S.; Picchi, D.F.; Galisteo-González, F.; Horcajada, P.; Marchal, J.A. Towards aMore Efficient Breast Cancer Therapy Using Active Human CellMembrane-Coated Metal–Organic Frameworks. Nanomaterials 2024, 14, 784. https://doi.org/10.3390/nano14090784
Sponsorship
Marie Skłodowska-Curie Action HeatNMof ITN under Grant ID: 860942; MCIN/AEI/10.13039/501100011033/FEDER “Una manera de hacer Europa” for funding PID2022-140151OB-C21 and PID2022-140151OB-C22; Chair “Doctors Galera-Requena in cancer stem cell research”; ProyExcel_00105 funded from Junta de Andalucía; Grant RYC2021-032522-I funded by MCIN/AEI /10.13039/501100011033; El FSE invierte en tu futuro and B-FQM-394; Ph.D. student fellowship FPU18/05336Abstract
The recent description of well-defined molecular subtypes of breast cancer has led to the
clinical development of a number of successful molecular targets. Particularly, triple-negative breast
cancer (TNBC) is an aggressive type of breast cancer with historically poor outcomes, mainly due to
the lack of effective targeted therapies. Recent progresses in materials science have demonstrated
the impressive properties of metal–organic framework nanoparticles (NPs) as antitumoral drug
delivery systems. Here, in a way to achieve efficient bio-interfaces with cancer cells and improve
their internalization, benchmarked MIL-100(Fe) NPs were coated with cell membranes (CMs) derived
from the human TNBC cell line MDA-MB-468. The prepared CMs-coated metal–organic framework
(CMs_MIL-100(Fe)) showed enhanced colloidal stability, cellular uptake, and cytotoxicity in MDAMB-
468 cells compared to non-coated NPs, paving the way for these human CMs-coated MIL-100(Fe)
NPs as effective targeted therapies against the challenging TNBC.